Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 25 percent increase over losses of $(0.24) per share from the same period last year. The company reported $7.00 thousand in sales this quarter. This is a 133.33 percent increase over sales of $3.00 thousand the same period last year.